The relevance of molecular biomarkers in cervical cancer patients treated with radiotherapy

被引:19
作者
Kilic, Sarah [1 ]
Cracchiolo, Bernadette [2 ]
Gabel, Molly [1 ,3 ]
Haffty, Bruce [1 ,3 ]
Mahmoud, Omar [1 ,3 ]
机构
[1] Rutgers State Univ, Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA
[2] Rutgers State Univ, Canc Inst New Jersey, Dept Gynecol Oncol, New Brunswick, NJ USA
[3] Rutgers State Univ, Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA
关键词
Cervical cancer; biomarker; radiation therapy; radioresistance;
D O I
10.3978/j.issn.2305-5839.2015.10.18
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Radiotherapy (RT) plays an integral role in the combined-modality management of cervical cancer. Various molecular mechanisms have been implicated in the adaptive cellular response to RT. Identification of these molecular processes may permit the prediction of treatment outcome and enhanced radiation-induced cancer cell killing through tailoring of the management approach, and/or the employment of selective inhibitors of these pathways. Methods: PubMed was searched for studies presenting biomarkers of cervical cancer radioresistance validated in patient studies or in laboratory experimentation. Results: Several biomarkers of cervical cancer radioresistance are validated by patient survival or recurrence data. These biomarkers fall into categories of biological function including hypoxia, cell proliferation, cell-cell adhesion, and evasion of apoptosis. Additional radioresistance biomarkers have been identified in exploratory experiments. Conclusions: Biomarkers of radioresistance in cervical cancer may allow molecular profiling of individual tumors, leading to tailored therapies and better prognostication and prediction of outcomes.
引用
收藏
页数:16
相关论文
共 123 条
[1]   American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].
Allegra, Carmen J. ;
Jessup, J. Milburn ;
Somerfield, Mark R. ;
Hamilton, Stanley R. ;
Hammond, Elizabeth H. ;
Hayes, Daniel F. ;
McAllister, Pamela K. ;
Morton, Roscoe F. ;
Schilsky, Richard L. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096
[2]   Perturbations of the AKT signaling pathway in human cancer [J].
Altomare, DA ;
Testa, JR .
ONCOGENE, 2005, 24 (50) :7455-7464
[3]   Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor [J].
An, J. ;
Chervin, A. S. ;
Nie, A. ;
Ducoff, H. S. ;
Huang, Z. .
ONCOGENE, 2007, 26 (05) :652-661
[4]  
Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209
[5]   iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human [J].
Bergamaschi, D ;
Samuels, Y ;
O'Neil, NJ ;
Trigiante, G ;
Crook, T ;
Hsieh, JK ;
O'Connor, DJ ;
Zhong, S ;
Campargue, I ;
Tomlinson, ML ;
Kuwabara, PE ;
Lu, X .
NATURE GENETICS, 2003, 33 (02) :162-167
[6]  
Bernhard EJ, 1996, CANCER RES, V56, P1727
[7]   Involvement of Members of the Cadherin Superfamily in Cancer [J].
Berx, Geert ;
van Roy, Frans .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2009, 1 (06) :a003129
[8]   Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86 [J].
Beskow, C. ;
Skikuniene, J. ;
Holgersson, A. ;
Nilsson, B. ;
Lewensohn, R. ;
Kanter, L. ;
Viktorsson, K. .
BRITISH JOURNAL OF CANCER, 2009, 101 (05) :816-821
[9]   Hypoxia, DNA repair and genetic instability [J].
Bristow, Robert G. ;
Hill, Richard P. .
NATURE REVIEWS CANCER, 2008, 8 (03) :180-192
[10]   Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens [J].
Britten, RA ;
Perdue, S ;
Opoku, J ;
Craighead, P .
RADIOTHERAPY AND ONCOLOGY, 1998, 48 (03) :329-334